Separation of two labeled components of [111In]-OctreoScan by HPLC

A. Bruskin, V. Tolmachev, J. E. Westlin, H. Lundqvist

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


[111In]-DTPA-D-Phe1-octreotide (OctreoScan®, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax®, Hewlett Packard), that OctreoScan® can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan® have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan®).

Original languageEnglish
Pages (from-to)95-99
Number of pages5
JournalJournal of Radioanalytical and Nuclear Chemistry
Issue number1
Publication statusPublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Analytical Chemistry
  • Nuclear Energy and Engineering
  • Radiology Nuclear Medicine and imaging
  • Pollution
  • Spectroscopy
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Separation of two labeled components of [<sup>111</sup>In]-OctreoScan by HPLC'. Together they form a unique fingerprint.

Cite this